MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012.
Guest UserNovember 2, 2012
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

International Consortium Awarded 6 Million Euro To Validate Pre-Eclampsia Early Detection Tests.

Guest UserNovember 5, 2012
Next

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury.

Guest UserOctober 25, 2012

© 2010-2025 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact